AbbVie Inc. (ABBV) News
Filter ABBV News Items
ABBV News Results
|Loading, please wait...|
ABBV News Highlights
- For ABBV, its 30 day story count is now at 99.
- Over the past 29 days, the trend for ABBV's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
- MG, TEVA and EYE are the most mentioned tickers in articles about ABBV.
Latest ABBV News From Around the Web
Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
Foreword As supplement to this article, please note that Kiplinger has published an online slide-show detailing the latest 2021 65 S&P Dividend Aristocrats. The article entitled 65 Best Dividend Stocks You Can Count On in 2021 is by Dan Burrows a contributing editor. While most of this collection of now...
In this article, we will take a look at the 10 best stocks for dividends. You can skip our detailed analysis of these dividend stocks’ outlook for 2021 and the merits of dividend investing and go directly to the 5 Best Stocks for Dividends. With the spread of the Delta variant exacerbating the pandemic-driven recession, […]
AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio.
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in favor of AbbVie. The new ruling found that Takeda is guilty of breach of contract for failing to supply its partner with the prostate cancer drug. AbbVie claims that Takeda is responsible for supply chain problems that have led to worldwide shortages. Takeda did not supply AbbVie with enough inventory to fulfill orders from April 2020 until at l
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress
AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ® (upadacitinib) in atopic dermatitis and new data on SKYRIZI® (risankizumab) in psoriasis and psoriatic arthritis, at the 30th European Academy of Dermatology and Venereology (EADV) Congress, to be held virtually on September 29-October 2.
The wild swings are enough to cause many investors to look for safe havens to park their hard-earned cash. Here's why those chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Prosper Junior Bakiny (AbbVie): Investors looking for safety in this volatile market can't go wrong with AbbVie.
At the lows of the market sell-off this week, the major U.S. market indices had all pulled back at least 5% from their respective all-time highs. While this type of market pullback typically happens at least once per year on average...we had yet to experience a 5% pullback in 2021...
Global Cat Eye Syndrome Market Technological Advancements & Competitive Insights To 2028||Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, AbbVie Inc., F. Hoffmann-La Roche Ltd
The comprehensive Cat Eye Syndrome market report gives information about historic data, present market trends, environment, technological innovation, forthcoming technologies and the technical progress in the related industry. All this market data aids healthcare industry to take better steps to